UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.335

Sortiert nach

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Arthritis research & therapy, 2019-05, Vol.21 (1), p.111-11, Article 111

2019

Link zum Volltext

Verfügbarkeit prüfen

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)

British journal of dermatology (1951), 2021-03, Vol.184 (3), p.437-449

2021

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

British journal of dermatology (1951), 2015-02, Vol.172 (2), p.484-493

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial

British journal of dermatology (1951), 2021-01, Vol.184 (1), p.50-59

2021

Link zum Volltext

Verfügbarkeit prüfen

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

British journal of dermatology (1951), 2020-05, Vol.182 (5), p.1120-1135

2020

Link zum Volltext

Verfügbarkeit prüfen

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.674-681

2018

Link zum Volltext

Verfügbarkeit prüfen

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

British journal of dermatology (1951), 2016-08, Vol.175 (2), p.273-286

2016

Link zum Volltext

Verfügbarkeit prüfen

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

British journal of dermatology (1951), 2020-03, Vol.182 (3), p.605-617

2020

Link zum Volltext

Verfügbarkeit prüfen

Conjunctivitis in dupilumab clinical trials

British journal of dermatology (1951), 2019-09, Vol.181 (3), p.459-473

2019

Link zum Volltext

Verfügbarkeit prüfen

Response to critical appraisal of LIBERTY AD CHRONOS

British journal of dermatology (1951), 2018-12, Vol.179 (6), p.1423-1423

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

British journal of dermatology (1951), 2018-09, Vol.179 (3), p.623-631

2018

Link zum Volltext

Verfügbarkeit prüfen

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

British journal of dermatology (1951), 2021-06, Vol.184 (6), p.1047-1058

2021

Link zum Volltext

Verfügbarkeit prüfen

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

British journal of dermatology (1951), 2022-03, Vol.186 (3), p.466-475

2022

Link zum Volltext

Verfügbarkeit prüfen

药物 Tildrakizumab 治疗斑块型银屑病的研究

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e208-e208

2020

Link zum Volltext

Verfügbarkeit prüfen

有多少人开发生物制剂 tildrakizumab 的抗药抗体, 以及这对其治疗有效性产生哪些影响

British journal of dermatology (1951), 2020-01, Vol.182 (1), p.e48-e48

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P)

British journal of dermatology (1951), 2018-06, Vol.178 (6), p.1315-1323

2018

Link zum Volltext

Verfügbarkeit prüfen

Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1264-1265

2021

Link zum Volltext

Verfügbarkeit prüfen

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

Journal of the European Academy of Dermatology and Venereology, 2019-12, Vol.33 (12), p.2305-2312

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.880-888

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

British journal of dermatology (1951), 2018-01, Vol.178 (1), p.132-139

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

British journal of dermatology (1951), 2018-09, Vol.179 (3), p.615-622

2018

Link zum Volltext

Verfügbarkeit prüfen

评估接受 Dupilumab 治疗的中度至重度特应性皮炎患者进行常规安全性检测的必要性

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e198-e198

2020

Link zum Volltext

Verfügbarkeit prüfen

Brodalumab 用于对乌司奴单抗应答不足的患者

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.e53-e53

2019

Link zum Volltext

Verfügbarkeit prüfen

一项在银屑病患者中开展的 tildrakizumab 药物研究

British journal of dermatology (1951), 2020-03, Vol.182 (3), p.e113-e113

2020

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

Journal of the European Academy of Dermatology and Venereology, 2021-01, Vol.35 (1), p.135-142

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.335

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(955)
Mit Volltextzugriff
(1.106)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

Conjunctivitis in dupilumab clinical trials

Response to critical appraisal of LIBERTY AD CHRONOS

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

药物 Tildrakizumab 治疗斑块型银屑病的研究

有多少人开发生物制剂 tildrakizumab 的抗药抗体, 以及这对其治疗有效性产生哪些影响

Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P)

Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

评估接受 Dupilumab 治疗的中度至重度特应性皮炎患者进行常规安全性检测的必要性

Brodalumab 用于对乌司奴单抗应答不足的患者

一项在银屑病患者中开展的 tildrakizumab 药物研究

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

Suchergebnisse filtern